Ono Pharmaceutical Co., Ltd. (OPHLF)
USD 10.89
(0.0%)
USD 10.89
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 372.66 Billion JPY | 11.4% |
| 2023 | 337.12 Billion JPY | 25.86% |
| 2022 | 267.85 Billion JPY | 19.73% |
| 2021 | 223.71 Billion JPY | 4.85% |
| 2020 | 213.35 Billion JPY | 4.18% |
| 2019 | 204.8 Billion JPY | 4.26% |
| 2018 | 196.44 Billion JPY | 9.58% |
| 2017 | 179.27 Billion JPY | 50.95% |
| 2016 | 118.76 Billion JPY | 18.01% |
| 2015 | 100.63 Billion JPY | -8.92% |
| 2014 | 110.5 Billion JPY | -0.82% |
| 2013 | 111.41 Billion JPY | -4.61% |
| 2012 | 116.79 Billion JPY | 5.7% |
| 2011 | 110.49 Billion JPY | -4.04% |
| 2010 | 115.14 Billion JPY | -0.08% |
| 2009 | 115.23 Billion JPY | -7.84% |
| 2008 | 125.03 Billion JPY | 3.66% |
| 2007 | 120.62 Billion JPY | -4.91% |
| 2006 | 126.85 Billion JPY | 2.07% |
| 2005 | 124.28 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | 81.1 Billion JPY | -19.29% |
| 2024 Q1 | 89.84 Billion JPY | 9.71% |
| 2024 Q3 | 100.49 Billion JPY | -3.47% |
| 2024 FY | 372.66 Billion JPY | 10.54% |
| 2024 Q2 | 104.1 Billion JPY | 15.87% |
| 2023 Q4 | 81.89 Billion JPY | -11.22% |
| 2023 Q2 | 83.2 Billion JPY | 4.29% |
| 2023 Q1 | 79.78 Billion JPY | 18.99% |
| 2023 FY | 337.12 Billion JPY | 25.86% |
| 2023 Q3 | 92.24 Billion JPY | 10.86% |
| 2022 Q3 | 72.28 Billion JPY | 13.04% |
| 2022 Q4 | 67.05 Billion JPY | -7.24% |
| 2022 FY | 267.85 Billion JPY | 19.73% |
| 2022 Q1 | 64.56 Billion JPY | 17.54% |
| 2022 Q2 | 63.94 Billion JPY | -0.96% |
| 2021 Q2 | 54.36 Billion JPY | 0.03% |
| 2021 Q1 | 54.35 Billion JPY | 9.55% |
| 2021 FY | 223.71 Billion JPY | 4.85% |
| 2021 Q4 | 54.92 Billion JPY | -8.56% |
| 2021 Q3 | 60.06 Billion JPY | 10.49% |
| 2020 Q3 | 56.4 Billion JPY | 4.28% |
| 2020 FY | 213.35 Billion JPY | 4.18% |
| 2020 Q4 | 49.61 Billion JPY | -12.04% |
| 2020 Q2 | 54.08 Billion JPY | 1.57% |
| 2020 Q1 | 53.25 Billion JPY | 10.48% |
| 2019 Q2 | 51.67 Billion JPY | 1.12% |
| 2019 Q3 | 53.83 Billion JPY | 4.19% |
| 2019 FY | 204.8 Billion JPY | 4.26% |
| 2019 Q4 | 48.2 Billion JPY | -10.47% |
| 2019 Q1 | 51.09 Billion JPY | 10.82% |
| 2018 Q4 | 46.11 Billion JPY | -22.35% |
| 2018 Q3 | 59.38 Billion JPY | 31.43% |
| 2018 Q2 | 45.18 Billion JPY | -1.29% |
| 2018 Q1 | 45.77 Billion JPY | 12.48% |
| 2018 FY | 196.44 Billion JPY | 9.58% |
| 2017 Q4 | 40.69 Billion JPY | -23.33% |
| 2017 FY | 179.27 Billion JPY | 50.95% |
| 2017 Q2 | 42.94 Billion JPY | 0.91% |
| 2017 Q1 | 42.55 Billion JPY | 17.16% |
| 2017 Q3 | 53.07 Billion JPY | 23.6% |
| 2016 Q4 | 36.32 Billion JPY | 18.35% |
| 2016 Q1 | 26.46 Billion JPY | 31.52% |
| 2016 Q2 | 25.28 Billion JPY | -4.49% |
| 2016 FY | 118.76 Billion JPY | 18.01% |
| 2016 Q3 | 30.69 Billion JPY | 21.4% |
| 2015 Q2 | 22.18 Billion JPY | -5.65% |
| 2015 FY | 100.63 Billion JPY | -8.92% |
| 2015 Q4 | 20.12 Billion JPY | -42.21% |
| 2015 Q3 | 34.82 Billion JPY | 57.02% |
| 2015 Q1 | 23.5 Billion JPY | -2.67% |
| 2014 FY | 110.5 Billion JPY | -0.82% |
| 2014 Q2 | 25.8 Billion JPY | -12.44% |
| 2014 Q3 | 31.06 Billion JPY | 20.35% |
| 2014 Q4 | 24.15 Billion JPY | -22.24% |
| 2014 Q1 | 29.47 Billion JPY | 18.93% |
| 2013 Q3 | 31.79 Billion JPY | 24.11% |
| 2013 FY | 111.41 Billion JPY | -4.61% |
| 2013 Q1 | 29.21 Billion JPY | 13.39% |
| 2013 Q4 | 24.78 Billion JPY | -22.04% |
| 2013 Q2 | 25.61 Billion JPY | -12.29% |
| 2012 Q4 | 25.76 Billion JPY | -25.02% |
| 2012 Q3 | 34.35 Billion JPY | 26.51% |
| 2012 Q2 | 27.15 Billion JPY | -8.01% |
| 2012 Q1 | 29.52 Billion JPY | 10.08% |
| 2012 FY | 116.79 Billion JPY | 5.7% |
| 2011 Q1 | 27.89 Billion JPY | 9.92% |
| 2011 Q2 | 24.7 Billion JPY | -11.45% |
| 2011 Q4 | 26.81 Billion JPY | -13.72% |
| 2011 FY | 110.49 Billion JPY | -4.04% |
| 2011 Q3 | 31.08 Billion JPY | 25.84% |
| 2010 Q1 | 30.96 Billion JPY | 14.24% |
| 2010 FY | 115.14 Billion JPY | -0.08% |
| 2010 Q2 | 26.25 Billion JPY | -15.21% |
| 2010 Q3 | 32.54 Billion JPY | 23.97% |
| 2010 Q4 | 25.37 Billion JPY | -22.03% |
| 2009 FY | 115.23 Billion JPY | -7.84% |
| 2009 Q2 | 25.88 Billion JPY | 0.0% |
| 2009 Q4 | 27.1 Billion JPY | -16.4% |
| 2009 Q3 | 32.42 Billion JPY | 25.27% |
| 2008 FY | 125.03 Billion JPY | 3.66% |
| 2007 FY | 120.62 Billion JPY | -4.91% |
| 2006 FY | 126.85 Billion JPY | 2.07% |
| 2005 FY | 124.28 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | -974.174% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | -986.075% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | -1136.522% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -3316310.074% |
| Novartis AG | 34.18 Billion USD | -990.046% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -50024.877% |